Drug Trial Radar · NCT04922021
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Jul 14, 2021
Primary completion
Jun 2, 2022
Study completion Sep 26, 2022
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side effects are when compared with a placebo injection with no medical ingredient. The study will last up to 36 weeks for each participant. The study will include a treatment period of 16 weeks, during which the participants will receive the injections, followed by a period of 16 weeks without treatment with the main purpose of continuing safety evaluations. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms and quality of life.
Conditions
- Atopic Dermatitis
Interventions
LEO 138559Drug
LEO 138559 is an antibody given by injection just under the skin.
LEO 138559 placeboDrug
LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in EASI Score From Baseline to Week 16Time frame: Week 0 to Week 16
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
LEO Pharma Investigational Site
Birmingham, Alabama
LEO Pharma Investigational Site
Fountain Valley, California
LEO Pharma Investigational Site
Los Angeles, California
LEO Pharma Investigational Site
Doral, Florida
LEO Pharma Investigational Site
Hialeah, Florida
LEO Pharma Investigational Site
Markham, Ontario, Canada
LEO Pharma Investigational Site
Mississauga, Ontario, Canada
LEO Pharma Investigational Site
Peterborough, Ontario, Canada
LEO Pharma Investigational Site
Berlin, Germany
LEO Pharma Investigational Site
Dresden, Germany
LEO Pharma Investigational Site
Leipzig, Germany
LEO Pharma Investigational Site
Lübeck, Germany
LEO Pharma Investigational Site
Krakow, Poland
LEO Pharma Investigational Site
Krakow, Poland
LEO Pharma nvestigational Site
Rzeszów, Poland
LEO Pharma Investigational Site
Warsaw, Poland
LEO Pharma Investigational Site
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.